Literature DB >> 27793578

Diagnostic value of sepsis biomarkers in hematopoietic stem cell transplant recipients in a condition of high prevalence of gram-negative pathogens.

Igor Stoma1, Igor Karpov2, Anatoly Uss3, Oleg Rummo3, Natalia Milanovich3, Igor Iskrov3.   

Abstract

OBJECTIVE/
BACKGROUND: A decision about the need for antimicrobial therapy in a patient with febrile neutropenia after hematopoietic stem cell transplantation (HSCT) is often complicated because of the low frequency of culture isolation and reduced clinical manifestation of infection. Usefulness and choice of sepsis biomarkers to distinguish bloodstream infection (BSI) from other causes of febrile episode is still argued in HSCT recipients in modern epidemiological situations characterized by the emergence of highly resistant gram-negative microorganisms. In this study a comparative analysis of diagnostic values of presepsin, procalcitonin (PCT), and C-reactive protein (CRP) was performed as sepsis biomarkers in adult patients after HSCT in a condition of high prevalence of gram-negative pathogens.
METHODS: A prospective observational clinical study was performed at the Center of Hematology and Bone Marrow Transplantation in Minsk, Republic of Belarus. The biomarkers (presepsin, PCT, and CRP) were assessed in a 4-hour period after the onset of febrile neutropenia episode in adult patients after HSCT. Microbiologically-confirmed BSI caused by a gram-negative pathogen was set as a primary outcome.
RESULTS: Clinical and laboratory data were analyzed in 52 neutropenic patients after HSCT aged 18-79years. Out of the biomarkers assessed, the best diagnostic value was shown in presepsin (area under the curve [AUC]: 0.889, 95% confidence interval [CI]: 0.644-0.987, p<.0001) with 75% sensitivity and 100% specificity, then in PCT (AUC: 0.741, 95% CI: 0.573-0.869, p=.0037) with 62% sensitivity and 88% specificity. The optimal cut-off value for CRP was set as 165mg/L, while it had an average diagnostic value (AUC: 0.707, 95% CI: 0.564-0.825, p=.0049) with low sensitivity (40%) and should not be routinely recommended as a biomarker in adult patients with suspected BSI after HSCT.
CONCLUSION: Presepsin may be recommended in adult patients with suspected gram-negative BSI after HSCT as a possible additional supplementary test with a cut-off value of 218pg/mL. PCT is inferior to presepsin in terms of sensitivity and specificity, but still shows a good quality of diagnostic value with an optimal cut-off value of 1.5ng/mL. CRP showed an average diagnostic value with low sensitivity (40%) and should not be routinely recommended as a biomarker in adult patients with suspected BSI after HSCT in a condition of high prevalence of gram-negative pathogens.
Copyright © 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bloodstream infections; C-reactive protein; Hematopoietic stem cell transplantation; Presepsin; Procalcitonin

Mesh:

Substances:

Year:  2016        PMID: 27793578     DOI: 10.1016/j.hemonc.2016.09.002

Source DB:  PubMed          Journal:  Hematol Oncol Stem Cell Ther


  8 in total

1.  Clinical utility of procalcitonin in bacterial infections in patients undergoing hematopoietic stem cell transplantation.

Authors:  Amit Bansal; Preethi Jeyaraman; S K Gupta; Nitin Dayal; Rahul Naithani
Journal:  Am J Blood Res       Date:  2020-12-15

2.  Impact of initial plasma presepsin level for clinical outcome in hospitalized patients with pneumonia.

Authors:  Motoi Ugajin; Yu Matsuura; Kei Matsuura; Hiroshi Matsuura
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

3.  Diagnostic Accuracy of Procalcitonin Compared to C-Reactive Protein and Interleukin 6 in Recognizing Gram-Negative Bloodstream Infection: A Meta-Analytic Study.

Authors:  Liying Lai; Yijie Lai; Hao Wang; Liang Peng; Ning Zhou; Yi Tian; Yongfang Jiang; Guozhong Gong
Journal:  Dis Markers       Date:  2020-01-23       Impact factor: 3.434

4.  Prognostic accuracy of SOFA, qSOFA and SIRS criteria in hematological cancer patients: a retrospective multicenter study.

Authors:  Lucie Probst; Enrico Schalk; Tobias Liebregts; Vanja Zeremski; Asterios Tzalavras; Michael von Bergwelt-Baildon; Nina Hesse; Johanna Prinz; Jörg Janne Vehreschild; Alexander Shimabukuro-Vornhagen; Dennis A Eichenauer; Jorge Garcia Borrega; Matthias Kochanek; Boris Böll
Journal:  J Intensive Care       Date:  2019-08-07

5.  Diagnostic Value of C-reactive Protein and Interleukin-8 in Risk Stratification of Febrile Neutropenic Children with Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Tang-Her Jaing; Chih-Chen Chang; Tsung-Yen Chang; Shih-Hsiang Chen; Yu-Chuan Wen; Pei-Kwei Tsay
Journal:  Sci Rep       Date:  2020-02-19       Impact factor: 4.379

6.  Analysis of Risk Factors and Clinical Indicators in Bloodstream Infections Among Patients with Hematological Malignancy.

Authors:  Yating Ma; Shijian Wang; Ming Yang; Jinfeng Bao; Chengbin Wang
Journal:  Cancer Manag Res       Date:  2020-12-31       Impact factor: 3.989

Review 7.  [Which biomarkers for diagnosis and guidance of anti-infection treatment in sepsis?]

Authors:  Johannes Ehler; Christoph Busjahn; Tobias Schürholz
Journal:  Anaesthesist       Date:  2021-11-12       Impact factor: 1.041

Review 8.  Presepsin as a Diagnostic and Prognostic Biomarker in Sepsis.

Authors:  Dimitrios Velissaris; Nicholas Zareifopoulos; Vasileios Karamouzos; Evangelos Karanikolas; Charalampos Pierrakos; Ioanna Koniari; Menelaos Karanikolas
Journal:  Cureus       Date:  2021-05-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.